The first of what are expected to be three bellwether cases involving the osteoporosis drug Fosamax began this week in New York. Plaintiffs in about 900 cases claim that Merck & Co. failed to warn that the drug may cause the death of jawbone tissue. Attorneys for the plaintiffs contend that Merck was aware of the potentially severe side effect as early as 1996.